trending Market Intelligence /marketintelligence/en/news-insights/trending/3cF6UlHr38D1yhJ4IBCuiA2 content esgSubNav
In This List

US FDA expands approval of Horizon treatment to include younger children

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA expands approval of Horizon treatment to include younger children

The U.S. Food and Drug Administration expanded the approval of Horizon Pharma Plc's Procysbi to include the treatment of children aged 1 year and above.

The drug, meant to treat a rare metabolic disorder called nephropathic cystinosis, is already approved for the treatment of adults and children as young as two years of age.

The approval was based on the results of a 17-patient study.